Thrombospondin-1 CD47 Signalling: From Mechanisms to Medicine.
Recent advances provide evidence that the cellular signalling pathway comprising the ligand-receptor duo of thrombospondin-1 (TSP1) and CD47 is involved in mediating a range of diseases affecting renal, vascular, and metabolic function, as well as cancer. In several instances, research has barely progressed past pre-clinical animal models of disease and early phase 1 clinical trials, while for cancers, anti-CD47 therapy has emerged from phase 2 clinical trials in humans as a crucial adjuvant therapeutic agent. This has important implications for interventions that seek to capitalize on targeting this pathway in diseases where TSP1 and/or CD47 play a role. Despite substantial progress made in our understanding of this pathway in malignant and cardiovascular disease, knowledge and translational gaps remain regarding the role of this pathway in kidney and metabolic diseases, limiting identification of putative drug targets and development of effective treatments. This review considers recent advances reported in the field of TSP1-CD47 signalling, focusing on several aspects including enzymatic production, receptor function, interacting partners, localization of signalling, matrix-cellular and cell-to-cell cross talk. The potential impact that these newly described mechanisms have on health, with a particular focus on renal and metabolic disease, is also discussed.
['Kale|Atharva|A|', 'Rogers|Natasha M|NM|', 'Ghimire|Kedar|K|0000-0002-4672-5256']
D051928:CD47 Antigen D002450:Cell Communication D006801:Humans D007668:Kidney D007674:Kidney Diseases D008659:Metabolic Diseases D009369:Neoplasms D015398:Signal Transduction D019700:Thrombospondin 1 D014652:Vascular Diseases
thrombospondin-1 (TSP1 CD47 (IAP) THBS1) ageing fibrosis glucose homeostasis kidney injury matricellular reactive oxygen species